Concord Biotech Limited has informed the Exchange about Copy of Newspaper Publication
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Biotech has informed the stock exchanges that its unaudited standalone and consolidated financial results for Q3 FY26 and the nine months ended December 31, 2025 were published in the Financial Express (English, all editions) and Financial Express (Gujarati, Ahmedabad edition) on February 12, 2026, as required under SEBI LODR Regulation 47. The underlying Q3 standalone numbers show revenue of Rs. 27,813.39 lakhs and net profit after tax of Rs. 6,778.27 lakhs (EPS Rs. 6.48). For the nine-month period, standalone revenue came in at Rs. 72,917.90 lakhs versus Rs. 77,020.31 lakhs in the prior year, and net profit fell to Rs. 17,324.46 lakhs from Rs. 23,102.69 lakhs — a roughly 25% year-on-year decline. The board approved these results at its meeting on February 11, 2026, and noted no material financial impact from the new Labour Codes for this quarter.
The filing itself is a routine procedural disclosure, but the published numbers reveal a meaningful year-on-year drop in both revenue and profit for the 9-month period, which investors may view negatively. The Labour Code assessment had no material impact, leaving the underlying business performance as the key takeaway for shareholders.